Oral pharmaceutical dosage forms

Abstract

Abuse-resistant oral dosage forms suitable for administration of pharmacologically active agents are provided.

We claim: 
     
       1. A composition comprising a mixture comprising:
 a methylphenidate or pharmaceutically acceptable salt thereof; 
 sucrose acetate isobutyrate (SAIB); 
 a cellulose acetate butyrate (CAB); 
 hydroxyethylcellulose (HEC); 
 about 0.01 wt % to about 5 wt % of a saturated polyglycolized glyceride (SPG); and 
 a solvent; 
 
       wherein the mixture is encapsulated within a capsule. 
     
     
       2. The composition of  claim 1 , wherein the methylphenidate or a pharmacologically acceptable salt thereof is present in an amount ranging from about 1.3 wt % to about 35 wt %. 
     
     
       3. The composition of  claim 1 , wherein the SAIB is present in an amount ranging from about 30 wt % to about 60 wt %. 
     
     
       4. The composition of  claim 1 , wherein the CAB has a number average molecular weight ranging from about 66,000 to about 83,000. 
     
     
       5. The composition of  claim 1 , wherein the CAB is present in an amount ranging from about 0.1 wt % to about 20 wt %. 
     
     
       6. The composition of  claim 1 , wherein the solvent is present in an amount ranging from about 0.1 wt % to about 40 wt %. 
     
     
       7. The composition of  claim 1 , wherein the mixture further comprises a rheology modifier. 
     
     
       8. The composition of  claim 1 , wherein the rheology modifier is present in an amount ranging from about 0.1 wt % to about 20 wt %. 
     
     
       9. The composition of  claim 1 , wherein the mixture further comprises a 6 silicon dioxide. 
     
     
       10. The composition of  claim 1 , wherein the mixture comprises methylphenidate. 
     
     
       11. The composition of  claim 1 , wherein the mixture comprises a pharmacologically acceptable salt of methylphenidate. 
     
     
       12. The composition of  claim 1 , wherein the mixture further comprises a rheology modifier selected from isopropyl myristate (IPM), caprylic/capric triglyceride, ethyl oleate, triethyl citrate, dimethyl phthalate, and benzyl benzoate. 
     
     
       13. The composition of  claim 1 , wherein the capsule comprises gelatin, hydroxyethylcellulose, or hydroxypropylmethylcellulose. 
     
     
       14. A pharmaceutical dosage form comprising the composition of  claim 1 . 
     
     
       15. The composition of  claim 1 , wherein the solvent is selected from triacetin, N-methyl-2-pyrrolidone, 2-pyrrolidone, dimethylsulfoxide, ethyl lactate, propylene carbonate, and gycofurol. 
     
     
       16. The composition of  claim 1 , wherein the solvent comprises triacetin.